CCDC50 and acute myeloid leukemia: By comparing the genetic features of BPDCN patients with sequential paired specimens, we observed that CCDC50 expression serves not only as a reliable marker for distinguishing BPDCN from AML in diagnostically challenging cases but also as an effective indicator for disease monitoring.